ESEva Slabá

Eva Slabá

*This is an algorithmically generated author record based on publicly available information.

Eva Slabá has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 July 2012
      • Vol. 32  (7) , 2849-54

    Effects of docetaxel, doxorubicin and cyclophosphamide on human breast cancer cell line MCF-7.

    by Marianna Trebunova, Galina Laputkova, Eva Slaba, Kamila Lacjakova, Aneta Verebova

    Cell viability assays are important tools in oncological research. The purpose of this study was to evaluate the effect of docetaxel, doxorubicin and cyclophosphamide on the metabolic activity of MCF-7 breast cancer cell line. Antiproliferative effect of cytostatics on MCF-7 cells was measured using the standard colorimetric test. The MCF-7 cell line was exposed to cytostatics for 24 hours. The metabolic activity was evaluated over the 24 hours. According to the statistical analysis, the change in the growth rate was significant (p<0.05) for the 120 nM docetaxel and above the 200 nM doxorubicin treatment in comparison with sensitive MCF-7 cells. When considering drugs in combination (60 nM docetaxel with 200 nM doxorubicin and 60 nM docetaxel with 500 nM doxorubicin) after the addition of 600 nM cyclophosphamide, we found a statistically significant decrease of metabolic activity of the MCF-7 cell line (p<0.05). Cyclophosphamide at 600 nM seems to enhance the influence of docetaxel when combined with doxorubicin.


  • The role of the −427T/C apolipoprotein E promoter polymorphism in the pathogenesis of Alzheimer’s disease, vascular dementia and mixed dementia

    by Marianna Trebuňová, Eva Slabá, Viera Habalová, Zuzana Gdovinová

    In this work, we explored the existence of genetic variant within the apolipoprotein E gene transcriptional regulatory region. Upon a population study, three polymorphic sites (−491, −427 and −219) and two mutations were found. We investigated newly reported −427T/C promoter polymorphism in association with sporadic Alzheimer’s disease (AD), vascular (VD) and mixed dementia (MD) along with APOE genotype and gender. Observed polymorphisms were investigated in 267 subjects, 122 of them formed a control group, the group of patients consisted of 145 subjects. Sixty patients were diagnosed with AD, 41 patients were diagnosed with VD and 35 patients left were diagnosed with MD in Slovak Caucasians (Central Europe). Gene–gene interaction analysis showed increase of the risk to develop AD in subjects carrying both the at least one C allele and the APOE E4 allele (OR = 17.93, 95%CI = 3.50–171.54).


    • 1 August 2008
      • Vol. 14  (8) , CR392-8

    Beta2-adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD.

    by Michal Mokry, Pavol Joppa, Eva Slaba, Jozef Zidzik, Viera Habalova, Zuzana Kluchova, Lydia Micietova, Eva Rozborilova, Jan Salagovic, Ruzena Tkacova

    The role of the beta2-adrenergic receptor (ADRB2) genotype in patients with chronic obstructive pulmonary disease (COPD) is unclear. In patients with acute exacerbations of COPD (AECOPD), we assessed the role of ADRB2 haplotypes in morning lung function and in the bronchodilator response to salbutamol. In 107 patients with AECOPD, polymorphisms in the amino acid position 16 (Arg16/Gly16) and 27 (Gln27/Glu27) of the ADRB2 gene were assessed by allele-specific polymerase chain reaction, identifying 31 subjects with the Gly16/Glu27-negative and 76 with the Gly16/Glu27-positive ADRB2 haplotype. Pulmonary function and bronchodilator response to salbutamol were assessed using bodyplethysmography. Forced expiratory volume in 1 second (FEV1) and peak expiratory flow (PEF) were significantly higher in the Gly16/Glu27-negative compared to the Gly16/Glu27-positive haplotype group at baseline (49.7+/-2.9% vs 42.4+/-1.8% predicted, P=0.037; 44.0+/-2.2% vs 36.4+/-1.6% predicted, P=0.008, respectively). FEV1, PEF, and forced vital capacity (FVC) increased from baseline to after salbutamol treatment in both the Gly16/Glu27-negative and the Gly16/Glu27-positive ADRB2 haplotype groups (P<0.001 for all comparisons). Values for FEV1 and PEF after administration of the bronchodilator were significantly higher in the Gly16/Glu27-negative haplotype group compared with the Gly16/Glu27-positive haplotype group (P=0.030 and P=0.034, respectively). No differences were observed in DeltaFEV1, DeltaPEF, or DeltaFVC after bronchodilation between the 2 ADRB2 haplotype groups (12.2+/-1.8% vs 14.5+/-1.5% predicted, P=0.393; 12.2+/-3.3% vs 20.8+/-3.2% predicted, P=0.117; 9.1+/-2.3% vs 10.4+/-1.9% predicted, P=0.707, respectively). The present findings suggest that the ADBR2 gene haplotypes may affect the severity of obstructive ventilatory impairment but not the immediate response to salbutamol during AECOPD.